|
KMID : 0614620240830030094
|
|
Korean Journal of Gastroenterology
2024 Volume.83 No. 3 p.94 ~ p.101
|
|
|
Current State of Pharmacotherapy in Obesity
|
|
Kim Won-Jun
|
|
|
Abstract
|
|
|
|
The prevalence of obesity with various complications is increasing rapidly in Korea. Although lifestyle modification is fundamental in obesity treatment, more effective treatment tools are required. Many advances in obesity treatment have been reported recently, including lifestyle modifications and pharmacological, endoscopic, and surgical treatments. Drugs with proven long-term efficacy and safety are preferred because management for obesity treatment is a long-term process. Currently, four medications are available for long-term use in Korea: Orlistat, Naltrexone/bupuropion NR, Phentermine/topiramate capsule, and Liraglutide. Recently, semaglutide and tirzepatide have been attracting attention because of their effectiveness and convenience, but they are not yet available in Korea. In addition, there are limitations such as the yo-yo effect when discontinuing the drug, long-term safety, and cost. Patients and medical staff must be aware of the advantages and side effects of each medication to ensure the successful treatment of obesity.
|
|
|
KEYWORD
|
|
|
Obesity, Pharmacotherapy, Glucagon-like peptide-1 receptor, Gastric inhibitory polypeptide
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|
|